SciSparc has received FDA approval to proceed with Phase IIb clinical trials for its first-in-class drug candidate SCI-110 in adult patients with Tourette Syndrome. The approval came within a month of the application submission on August 23, 2024. The trial will be conducted at three leading centers: Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center.The Phase IIb trial will evaluate the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65 years through daily oral treatment. Patients will be randomized 1:1 to receive either SCI-110 or placebo. The primary efficacy endpoint will measure tic severity changes using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline.The company has already secured Institutional Review Board approvals from all three clinical sites and related federal administrations. This milestone reinforces SciSparc's ambition to become a leading provider of treatments for central nervous system disorders, building on the excellent results from their previous Phase IIa clinical trial.

SciSparc has received FDA approval to proceed with Phase IIb clinical trials for its first-in-class drug candidate SCI-110 in adult patients with Tourette Syndrome. The approval came within a month of the application submission on August 23, 2024. The trial will be conducted at three leading centers: Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center.The Phase IIb trial will evaluate the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65 years through daily oral treatment. Patients will be randomized 1:1 to receive either SCI-110 or placebo. The primary efficacy endpoint will measure tic severity changes using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline.The company has already secured Institutional Review Board approvals from all three clinical sites and related federal administrations. This milestone reinforces SciSparc's ambition to become a leading provider of treatments for central nervous system disorders, building on the excellent results from their previous Phase IIa clinical trial.